Novo Nordisk NVO announced that it has ended its collaboration with telehealth provider Hims & Hers Health. In addition, the ...

Novo Nordisk (NYSE: NVO) stock jumped 3% through 10:55 a.m. Tuesday on some potentially positive news in the GLP-1 weight loss market. As Reuters reports today, an online weight loss company ...

Novo Nordisk (NVO-4.81%) stock jumped 3% through 10:55 a.m. Tuesday on some potentially positive news in the GLP-1 weight loss market.. As Reuters reports today, an online weight loss company ...

Ozempic and Wegovy maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.

Novo Nordisk's share price is down 54% from its peak in June 2024. Its U.S.-listed shares fell another 3% in premarket trading Friday. The company, headquartered in Bagsvaerd, ...

Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.

Novo Nordisk’s value more than quintupled between 2017 and 2024, but the company’s shares have fallen sharply since late last year, weighed down by Big Pharma rivals catching up and the ...

Novo Nordisk's competitive position is strengthening, driven by strong sales growth in Wegovy, Ozempic, and rare diseases. See why NVO stock is a Buy.

Novo Nordisk is partnering with online telehealth companies to sell a direct-to-consumer, lower cost version of its popular weight-loss drug Wegovy. The pharmaceutical company announced it would ...

Shares of Novo Nordisk (NYSE: NVO) are up on Tuesday. The company's stock gained 3.9% as of 2:40 p.m. ET today and was up as much as 4.5% earlier in the day. The move up comes as the S&P 500 and ...

Novo Nordisk (NVO-4.27%), the Danish drugmaker of GLP-1 weight loss drugs Ozempic and Wegovy, slipped 2% through 10:30 a.m. ET Friday after suffering a one-two punch from Reuters and a bank analyst.